Rho-associated protein kinase
Crystal structure of human ROCK I
|Symbol||Rho-associated protein kinase|
|Alt. symbols||Rho-associated, coiled-coil-containing protein kinase|
Rho-associated protein kinase (ROCK) is a kinase belonging to the AGC (PKA/ PKG/PKC) family of serine-threonine kinases. It is involved mainly in regulating the shape and movement of cells by acting on the cytoskeleton.
ROCKs (ROCK1 and ROCK2) occur in mammals (human, rat, mouse, cow), zebrafish, Xenopus, invertebrates (C. elegans, Mosquito, Drosophila) and chicken. Human ROCK1 has a molecular mass of 158 kDa and is a major downstream effector of the small GTPase RhoA. Mammalian ROCK consists of a kinase domain, a coiled-coil region and a Pleckstrin homology (PH) domain, which reduces the kinase activity of ROCKs by an autoinhibitory intramolecular fold if RhoA-GTP is not present.
Rat ROCKs were discovered as the first effectors of Rho and they induce the formation of stress fibers and focal adhesions by phosphorylating MLC (myosin light chain). Due to this phosphorylation, the actin binding of myosin II and, thus, the contractility increases. Two mouse ROCK isoforms ROCK1 and ROCK2 have been identified. ROCK1 is mainly expressed in the lung, liver, spleen, kidney and testis. However, ROCK2 is distributed mostly in the brain and heart.
1. ROCK is a key regulator of actin organization and thus a regulator of cell migration as follows:
Different substrates can be phosphorylated by ROCKs, including LIM kinase, myosin light chain (MLC) and MLC phosphatase. These substrates, once phosphorylated, regulate actin filament organization and contractility as follows:
- Amount of actin filaments
ROCK inhibits the depolymerization of actin filaments indirectly: ROCK phosphorylates and activates LIM kinase, which in turn phosphorylates ADF/cofilin, thereby inactivating its actin-depolymerization activity. This results in the stabilization of actin filaments and an increase in their numbers. Thus, over time actin monomers that are needed to continue actin polymerization for migration become limited. The increased stable actin filaments and the loss of actin monomers contribute to a reduction of cell migration.
- Cellular contractility
- Firstly, phosphorylation of the myosin light chain (MLC) increases the myosin II ATPase activity. Thus several bundled and active myosins, which are asynchronously active on several actin filaments, move actin filaments against each other, resulting in the net shortenting of actin fibres.
- Secondly, ROCK inactivates MLC phosphatase, leading to increased levels of phosphorylated MLC.
Thus in both cases, ROCK activation by Rho induces the formation of actin stress fibers, actin filament bundles of opposing polarity, containing myosin II, tropomyosin, caldesmon and MLC-kinase, and consequently of focal contacts, which are immature integrin-based adhesion points with the extracellular substrate.
2. Other functions and targets
- RhoA-GTP stimulates the phospholipid phosphatase activity of PTEN (phosphatase and tensin homologue), a human tumor suppressor protein. This stimulation seems to depend on ROCK. In this way, PTEN is important to prevent uncontrolled cell division as is exhibited in cancer cells.
- ROCK plays an important role in cell cycle control, it seems to inhibit the premature separation of the two centrioles in G1, and is proposed to be required for contraction of the cleavage furrow, which is necessary for the completion of cytokinesis.
- ROCKs also seem to antagonize the insulin signaling pathway, resulting in a reduction of cell size and influence cell fate.
- ROCKS play a role in membrane blebbing, a morphological change seen in cells committed to apoptosis. The pro-apoptotic protease, caspase 3, activates ROCK kinase activity by cleaving the C-terminal PH domain. As a result, the autoinhibitory intramolecular fold of ROCK is abolished. ROCK also regulates MLC phosphorylation and actomyosin contractility, which regulate membrane blebbing.
- ROCKs contribute to neurite retraction by inducing growth cone collapse by activating actomyosin contractility. It is also possible that phosphorylation of collapsin response mediator protein-2 (CRMP2) by ROCK inhibits CRPM2 function of promoting axon outgrowth, resulting in growth cone collapse.
- ROCKs regulate cell-cell adhesion: Loss of ROCK activity seems to lead to loss of tight junction integrity in endothelial cells. In epithelial cells inhibition of ROCK seems to decrease tight junction integrity. Active ROCK in these cells seems to stimulate the disruption of E-Cadherin-mediated cell-cell contacts by activating actomyosin contractility.
3. Other ROCK targets
- NHE1 (a sodium hydrogen exchanger, involved in focal adhesions and actin organisation)
- intermediate filament proteins: Vimentin, GFAP (glial fibrillaric acidic protein), NF-L (neurofilament L protein)
- F-actin binding proteins: Adducin, EF-1&alpha (elongation factor, translation co-factor), MARCKS (myristylated alanine-rich C kinase substrate), Caponin (unknown function), and ERM (involved in linkage of the actin cytoskelton to the plasma membrane).
|Rho-associated, coiled-coil-containing protein kinase 1|
|Rho-associated, coiled-coil-containing protein kinase 2|
ROCKs are homologous to other metazoan kinases such as myotonic dystrophy kinase (DMPK), DMPK-related cell division control protein 42 (Cdc42)-binding kinases (MRCK) and citron kinase. All of theses kinases are composed of a N-terminal kinase domain, a coiled-coil structure and other functional motifs at the C-terminus
ROCK is a downstream effector molecule of the Rho GTPase Rho that increases ROCK kinase activity when bound to it.
ROCK activity is regulated by the disruption of an intramolecular autoinhibition. In general, the structure of ROCK proteins consists of an N-terminal kinase domain, a coiled-coiled region and a PH domain containing a cystein-rich domain (CRD) at the C-terminal. A Rho-binding domain (RBD) is located in close proximity just in front of the PH domain.
The kinase activity is inhibited by the intramolecular binding between the C-terminal cluster of RBD domain and the PH domain to the N-terminal kinase domain of ROCK. Thus, the kinase activity is off when ROCK is intramolecularly folded. The kinase activity is switched on when Rho-GTP binds to the Rho-binding domain of ROCK, disrupting the autoinhibitory interaction within ROCK, which liberates the kinase domain because ROCK is then no longer intramolecularly folded.
It has also been shown that Rho is not the only activator of ROCK. ROCK can also be regulated by lipids, in particular arachidonic acid, and protein oligomerization, which induces N-terminal transphosphorylation.
Recent research has shown that ROCK signaling plays an important role in many diseases including diabetes, intracerebral hemorrhage, neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis, pulmonary hypertension and cancer. It has been shown to be involved in causing tissue thickening and stiffening around tumours in a mouse model of skin cancer, principally by increasing the amount of collagen in the tissue around the tumour.
Researchers are developing ROCK inhibitors for treating disease. For example, such drugs have potential to prevent cancer from spreading by blocking cell migration, stopping cancer cells from spreading into neighbouring tissue.
- Hahmann C, Schroeter T (2010). "Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity". Cell Mol Life Sci. 67 (2): 171–7. doi:10.1007/s00018-009-0189-x. PMID 19907920.
- Riento K, Ridley AJ (2003). "Rocks: multifunctional kinases in cell behaviours". Nat Rev Mol Cell Biol. 4 (6): 446–56. doi:10.1038/nrm1128. PMID 12778124.
- Leung T, Chen XQ, Manser E, Lim L (October 1996). "The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton". Mol. Cell. Biol. 16 (10): 5313–27. PMC 231530. PMID 8816443.
- Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S (August 1996). "ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice". FEBS Lett. 392 (2): 189–93. doi:10.1016/0014-5793(96)00811-3. PMID 8772201.
- Maekawa M, Ishizaki T, Boku S, et al. (August 1999). "Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase". Science. 285 (5429): 895–8. doi:10.1126/science.285.5429.895. PMID 10436159.
- Wang Y, Zheng XR, Riddick N, et al. (February 2009). "ROCK Isoform Regulation of Myosin Phosphatase and Contractility in Vascular Smooth Muscle Cells". Circ. Res. 104 (4): 531–40. doi:10.1161/CIRCRESAHA.108.188524. PMC 2649695. PMID 19131646.
- Li Z, Dong X, Dong X, et al. (April 2005). "Regulation of PTEN by Rho small GTPases". Nat. Cell Biol. 7 (4): 399–404. doi:10.1038/ncb1236. PMID 15793569.
- "Entrez Gene: PTEN phosphatase and tensin homolog (mutated in multiple advanced cancers 1)".
- Gao SY, Li CY, Chen J, et al. (2004). "Rho-ROCK signal pathway regulates microtubule-based process formation of cultured podocytes--inhibition of ROCK promoted process elongation". Nephron Exp. Nephrol. 97 (2): e49–61. doi:10.1159/000078406. PMID 15218323.
- Drechsel DN, Hyman AA, Hall A, Glotzer M (January 1997). "A requirement for Rho and Cdc42 during cytokinesis in Xenopus embryos". Curr. Biol. 7 (1): 12–23. doi:10.1016/S0960-9822(06)00023-6. PMID 8999996.
- Kosako H, Yoshida T, Matsumura F, Ishizaki T, Narumiya S, Inagaki M (December 2000). "Rho-kinase/ROCK is involved in cytokinesis through the phosphorylation of myosin light chain and not ezrin/radixin/moesin proteins at the cleavage furrow". Oncogene. 19 (52): 6059–64. doi:10.1038/sj.onc.1203987. PMID 11146558.
- Yasui Y, Amano M, Nagata K, et al. (November 1998). "Roles of Rho-associated Kinase in Cytokinesis; Mutations in Rho-associated Kinase Phosphorylation Sites Impair Cytokinetic Segregation of Glial Filaments". J. Cell Biol. 143 (5): 1249–58. doi:10.1083/jcb.143.5.1249. PMC 2133074. PMID 9832553.
- Piekny AJ, Mains PE (June 2002). "Rho-binding kinase (LET-502) and myosin phosphatase (MEL-11) regulate cytokinesis in the early Caenorhabditis elegans embryo". J. Cell. Sci. 115 (Pt 11): 2271–82. PMID 12006612.
- Han X, Lan X, Li Q, Gao Y, Zhu W, Cheng T, Maruyama T, Wang J (2015). "Inhibition of prostaglandin E2 receptor EP3 mitigates thrombin-induced brain injury.". J Cereb Blood Flow Metab. doi:10.1177/0271678X15606462. PMID 26661165.
- Tönges L, Frank T, et al. (2012). "Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease". Brain. 135(Pt 11):3355-70 (11): 3355–70. doi:10.1093/brain/aws254. PMC 3501973. PMID 23087045.
- Dahal BK, Kosanovic D, et al. (2010). "Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension". European Respiratory Journal. 36(4):808-18 (4): 808–18. doi:10.1183/09031936.00140309. PMID 20530035.
- Samuel, MS.; Lopez, JI.; McGhee, EJ.; Croft, DR.; Strachan, D.; Timpson, P.; Munro, J.; Schröder, E.; et al. (Jun 2011). "Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce interfollicular epidermal hyperplasia and tumor growth". Cancer Cell. 19 (6): 776–91. doi:10.1016/j.ccr.2011.05.008. PMC 3115541. PMID 21665151.